Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003056 · ClinicalTrials.gov registry record · Phase 3
Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 105
- Enrollment target
NCT00003056 is a Phase 3 study that was terminated before completion, run by Baxalta now part of Shire. The registered enrollment target is 105 participants.
The verdict
NCT00003056, a Phase 3 study, was terminated before completion, sponsored by Baxalta now part of Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 105 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. PURPOSE: Randomized phase III trial to compare the effectiveness of cyclosporine plus methotrexate with cyclosporine plus T cell depletion for prevention of graft-versus-host disease during peripheral stem cell transplantation in patients who have advanced leukemia or lymphoma who are eligible for transplanted peripheral stem cells from a donor.
Interventions
- DRUG cyclosporine
- DRUG cyclosporine and methotrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 1997-04-01 |
| Est. Completion | 2003-06-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003056
The ClinicalTrials.gov registry entry for NCT00003056 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclosporine is the first listed.
NCT00003056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003056 about?
NCT00003056 is a clinical study titled "Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells can make an immune response against the body's normal tissues. PURPOSE: Randomized phase III trial ...
What is the current status of trial NCT00003056?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 105 participants. The study started on 1997-04-01. Estimated completion is 2003-06-01.
What interventions are being tested in trial NCT00003056?
The interventions under investigation include: cyclosporine (DRUG), cyclosporine and methotrexate (DRUG).
Who is sponsoring clinical trial NCT00003056?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.